Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease

NCT: NCT04395131 · COMPLETED

NCT IDNCT04395131
StatusCOMPLETED
Start Date2020-04-03
Completion2020-08-14

Brief Summary

The study will be a prospective, interventional, non-randomized, single-center study in 20 ESRD patients on hemodialysis. The study will compare performance of the Clearum HS dialyzer to typical values obtained with other commercially available high flux dialyzers. In addition, the Clearum HS dialyzer will be compared to a Fresenius FX80 dialyzer for a baseline (control) comparison. This will be a post-market study. The duration of the trial is 2 weeks for the FX80 control dialyzer + 6 weeks with the Clearum HS dialyzer used for 3x weekly high flux hemodialysis.

Frequently Asked Questions

What is Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease?

Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease is a clinical trial registered under NCT04395131. Current status: COMPLETED.

What is the status of NCT04395131?

The current status of NCT04395131 (Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease) is: COMPLETED.

When did Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease start?

Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease started on 2020-04-03.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑